Respiratory Syncytial Virus (RSV) Infection (DBCOND0079390)

Identifiers

Synonyms

Respiratory Syncytial Virus (RSV) Infections / Syncytial Virus Respiratory Infection / RSV Infection / Infections, Respiratory Syncytial Virus / Respiratory Syncytial Virus Infections / Respiratory Syncytial Virus Infection / Respiratory syncytial virus infection (disorder) / Respiratory syncytial virus infection NOS

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Respiratory syncytial virus vaccine, adjuvanted	An adjuvanted respiratory syncytial virus vaccine in older adults.	No drug targets

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02718937	Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study	No drug interventions	treatment	2	completed
NCT04144816	Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants	No drug interventions	Not Available	Not Available	unknown_status
NCT06259487	Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.	No drug interventions	prevention	Not Available	recruiting
NCT05550545	Infant RSV Infections and Health-related Quality of Life of Families	No drug interventions	Not Available	Not Available	recruiting
NCT01483911	ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers	Gontivimab	treatment	1	completed
NCT06180993	Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization	Nirsevimab	Not Available	Not Available	recruiting
NCT03755778	Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects	Itraconazole Quinidine Rifampin	basic_science	1	completed
NCT04743609	RSV Burden in Outpatient Settings	No drug interventions	Not Available	Not Available	recruiting
NCT03387137	Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children	No drug interventions	prevention	1	completed
NCT04520659	Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age	No drug interventions	prevention	1	active_not_recruiting
NCT03171142	Effect of Heliox on RSV Bronchiolitis	Oxygen	treatment	3	completed
NCT04782336	Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test	No drug interventions	diagnostic	Not Available	suspended
NCT06318936	Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The Netherlands	No drug interventions	Not Available	Not Available	recruiting
NCT03062917	Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis	No drug interventions	diagnostic	Not Available	completed
NCT04871724	Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects	Fluconazole	treatment	1	completed
NCT05765396	SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies	No drug interventions	Not Available	Not Available	recruiting
NCT04690335	Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine	No drug interventions	prevention	2	completed
NCT04484935	Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children	Nirsevimab	prevention	2	completed
NCT04531735	Respiratory Syncytial Virus Infection May be More Dangerous in Neonate	No drug interventions	Not Available	Not Available	unknown_status
NCT05118386	Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults	No drug interventions	treatment	1	completed
NCT04938830	Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)	Clesrovimab Palivizumab	prevention	3	active_not_recruiting
NCT03621930	RESCEU Study, Defining the Burden of Disease of RSV in Older Adults	No drug interventions	Not Available	Not Available	unknown_status
NCT01875926	ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers	Gontivimab	treatment	1	completed
NCT06401720	Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection	No drug interventions	Not Available	Not Available	enrolling_by_invitation
NCT04944160	Impact of the Covid-19 on Respiratory Syncytial Virus (RSV) Epidemic	No drug interventions	Not Available	Not Available	completed
NCT03909867	Emission Patterns of Respiratory Syncytial Virus	No drug interventions	Not Available	Not Available	suspended
NCT06204367	Evaluation of Lung Ultrasonography Findings in Newborns With Respiratory Syncytial Virus Bronchiolitis	No drug interventions	Not Available	Not Available	enrolling_by_invitation
NCT03596801	Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children	No drug interventions	prevention	1	active_not_recruiting
NCT03627572	RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants	No drug interventions	Not Available	Not Available	unknown_status
NCT05618769	Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm Infants	No drug interventions	prevention	Not Available	recruiting
NCT05794412	Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT05779995	A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV	No drug interventions	treatment	1 / 2	recruiting
NCT06585150	Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection	Obeldesivir	treatment	2	not_yet_recruiting
NCT03384823	A Study of EDP-938 in Healthy Subjects	No drug interventions	treatment	1	completed
NCT03691623	A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model	No drug interventions	treatment	2	completed
NCT05765838	Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.	No drug interventions	diagnostic	Not Available	recruiting
NCT05727202	Project STARFISH - PRJ0002679	No drug interventions	Not Available	Not Available	completed
NCT03698084	RESCEU: Defining the Burden of RSV Disease	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT01475305	Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)	No drug interventions	prevention	1	terminated
NCT03750383	Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects	Cyclosporine Prednisone	basic_science	1	completed
NCT01801293	A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806	Presatovir	treatment	1	completed
NCT05587478	A Study of EDP-323 in Healthy Subjects	No drug interventions	treatment	1	completed
NCT06286007	Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control	No drug interventions	Not Available	Not Available	recruiting
NCT05928507	FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT05070975	Severity of RSV Infections in Twins	No drug interventions	Not Available	Not Available	completed
NCT06170242	A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model	No drug interventions	treatment	2	recruiting
NCT05568706	A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.	No drug interventions	treatment	2	recruiting
NCT06490549	An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)	No drug interventions	Not Available	Not Available	recruiting
NCT03728413	The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus	No drug interventions	basic_science	Not Available	recruiting
NCT04498741	Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects	Dabigatran Midazolam Rosuvastatin Tacrolimus	basic_science	1	completed
NCT06442241	A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults	No drug interventions	prevention	1	not_yet_recruiting
NCT05348616	Impact of the Covid-19 on RSV	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT05268939	Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19	No drug interventions	diagnostic	Not Available	completed
NCT04267822	Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV	Sisunatovir	treatment	2	withdrawn
NCT05661422	Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric Patients	No drug interventions	Not Available	Not Available	withdrawn
NCT06008457	Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit	No drug interventions	Not Available	Not Available	completed
NCT01090557	Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study	No drug interventions	Not Available	Not Available	completed
NCT06583031	Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years	No drug interventions	prevention	1	not_yet_recruiting
NCT06172660	Real-World Effectiveness of Perinatal RSV Immunoprophylaxis	Nirsevimab	Not Available	Not Available	not_yet_recruiting
NCT05767294	Epidemiological and Clinical Characteristics of Hospitalized Patients Under 5 Years Old With RSV Infection in Central China, Wuhan	No drug interventions	Not Available	Not Available	enrolling_by_invitation
NCT03919591	RSV Study in Adults 60 to 75 Years of Age	No drug interventions	basic_science	Not Available	completed
NCT05105191	Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room	No drug interventions	diagnostic	Not Available	terminated
NCT04752644	Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults	Modified vaccinia ankara	treatment	2	completed
NCT01905215	Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines	No drug interventions	prevention	1	completed
NCT02201303	Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression	Danirixin	other	1	completed
NCT05921903	A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	2	active_not_recruiting
NCT05590403	A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	completed
NCT05966090	A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults	Human varicella-zoster immune globulin Respiratory syncytial virus vaccine, adjuvanted Varicella zoster vaccine (recombinant)	prevention	3	active_not_recruiting
NCT03624790	Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers	No drug interventions	prevention	1	recruiting
NCT00316264	Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season	Motavizumab Palivizumab	prevention	2	completed
NCT01805921	RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.	Modified vaccinia ankara	prevention	1	completed
NCT04288921	Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites	No drug interventions	diagnostic	Not Available	recruiting
NCT00496821	Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus	Asvasiran	treatment	2	completed
NCT05547087	A Dose Finding Study of VN-0200	No drug interventions	prevention	2	completed
NCT06389487	A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	recruiting
NCT04681833	Safety and Efficacy of BARS13 in the Elderly	No drug interventions	prevention	2	active_not_recruiting
NCT04841577	A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	completed
NCT03674177	A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women	No drug interventions	prevention	1	completed
NCT06313697	A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult	No drug interventions	treatment	1	recruiting
NCT05568797	A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above	Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated) Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated) Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/9/2014 antigen (formaldehyde inactivated) Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated) Influenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated) Respiratory syncytial virus vaccine, adjuvanted	prevention	3	completed
NCT03191383	A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers	No drug interventions	prevention	2	withdrawn
NCT01968083	Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children	No drug interventions	prevention	1	completed
NCT01754428	Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age	No drug interventions	Not Available	Not Available	completed
NCT06216093	Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years	No drug interventions	prevention	1	recruiting
NCT01155193	Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany	No drug interventions	Not Available	Not Available	completed
NCT04732871	Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	active_not_recruiting
NCT02231671	A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176	Lumicitabine	basic_science	1	completed
NCT00111878	Study to Evaluate MEDI-534 in Healthy Adults	No drug interventions	Not Available	Not Available	completed
NCT05879107	Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults	Respiratory syncytial virus vaccine, adjuvanted Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 10a capsular polysaccharide antigen Streptococcus pneumoniae type 11A capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 11a capsular polysaccharide antigen Streptococcus pneumoniae type 12F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 12f capsular polysaccharide antigen Streptococcus pneumoniae type 14 capsular polysaccharide antigen Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 15b capsular polysaccharide antigen Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 18c capsular polysaccharide antigen Streptococcus pneumoniae type 19A capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 19a capsular polysaccharide antigen Streptococcus pneumoniae type 19f capsular polysaccharide antigen Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 23f capsular polysaccharide antigen Streptococcus pneumoniae type 3 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 4 capsular polysaccharide antigen Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 5 capsular polysaccharide antigen Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 6a capsular polysaccharide antigen Streptococcus pneumoniae type 6b capsular polysaccharide antigen Streptococcus pneumoniae type 7F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 7f capsular polysaccharide antigen Streptococcus pneumoniae type 8 capsular polysaccharide antigen Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 9v capsular polysaccharide antigen	prevention	3	completed
NCT04919109	Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children	No drug interventions	prevention	1	recruiting
NCT00493285	Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age	No drug interventions	prevention	1	completed
NCT00429637	Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients	No drug interventions	Not Available	Not Available	unknown_status
NCT06197152	Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV	No drug interventions	Not Available	Not Available	recruiting
NCT06328400	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension	No drug interventions	treatment	1	completed
NCT04605159	A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers	No drug interventions	prevention	3	terminated
NCT03379675	A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus	Rilematovir	treatment	2	completed
NCT02360475	Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women	Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis pertactin antigen (formaldehyde inactivated) Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	prevention	2	completed
NCT02387606	Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.	Rilematovir	treatment	2	completed
NCT05026749	Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children	No drug interventions	treatment	3	recruiting
NCT01290419	Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine	No drug interventions	treatment	1	completed
NCT01355016	A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers	No drug interventions	treatment	1	completed
NCT02460016	A Study of AK0529 in Infants Hospitalized With RSV	Racepinephrine	treatment	1	terminated
NCT04090658	A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults	No drug interventions	prevention	1	completed
NCT01065935	Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)	Asvasiran	treatment	2	completed
NCT02873286	RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults	No drug interventions	other	2	completed
NCT01960686	RSV F Dose-Ranging Study in Women	No drug interventions	treatment	2	completed
NCT02755948	A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers	Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)	basic_science	Not Available	terminated
NCT00129766	Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children	Motavizumab Palivizumab	prevention	3	completed
NCT01852266	Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children	No drug interventions	prevention	1	completed
NCT00192465	Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults	Motavizumab	prevention	1	completed
NCT04914520	Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects	No drug interventions	prevention	1	completed
NCT01756482	Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)	Presatovir	treatment	2	completed
NCT05964582	Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT03382431	A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study	No drug interventions	treatment	1 / 2	completed
NCT05630573	A Study of TNM001 in Chinese Healthy Preterm and Term Infants	No drug interventions	prevention	1 / 2	completed
NCT02948127	Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age	No drug interventions	prevention	1	terminated
NCT05559476	A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	completed
NCT01915394	Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)	No drug interventions	Not Available	Not Available	completed
NCT02419391	Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine	Modified vaccinia ankara	prevention	1	completed
NCT02325791	Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants	Suptavumab	treatment	3	completed
NCT03782662	A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants	Itraconazole Midazolam Rifampin Sisunatovir Verapamil	treatment	1	completed
NCT05970744	Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years	No drug interventions	prevention	1	completed
NCT05059301	A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	completed
NCT01502072	Respiratory Syncytial Virus - RSV Protocol	Ribavirin	treatment	2	completed
NCT05229068	A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy	No drug interventions	prevention	3	withdrawn
NCT06033612	Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults	Midazolam	treatment	1	completed
NCT02601612	Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children	No drug interventions	prevention	1	completed
NCT04227210	Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults	No drug interventions	prevention	1	completed
NCT04925310	Infection With Respiratory Syncytial Virus in Infants	No drug interventions	Not Available	Not Available	unknown_status
NCT02786381	Idylla IFV-RSV Panel Clinical Testing	No drug interventions	Not Available	Not Available	completed
NCT06573281	A Study on the Safety of and Immune Response to Different Doses of an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years	No drug interventions	prevention	1	not_yet_recruiting
NCT04431050	Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens	No drug interventions	Not Available	Not Available	unknown_status
NCT05642403	A Study of XW001 in Healthy Adult Subjects	No drug interventions	treatment	1	completed
NCT03814590	A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults	No drug interventions	prevention	1 / 2	completed
NCT05873764	A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants	Sisunatovir	treatment	1	completed
NCT01906164	Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers	Lumicitabine	treatment	1	completed
NCT03699202	Anti-RSV Study in Chinese Patients (ASCENT)	Ziresovir	treatment	2	unknown_status
NCT03258502	A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection	Sisunatovir	treatment	2	completed
NCT04444284	Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children	No drug interventions	prevention	1	completed
NCT04633187	Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract	No drug interventions	treatment	2	terminated
NCT02478333	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants	Lumicitabine	Not Available	1	completed
NCT01893554	Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children	No drug interventions	prevention	1	active_not_recruiting
NCT02593851	A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection	Rilematovir	treatment	1	terminated
NCT04851977	A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants	No drug interventions	prevention	1	completed
NCT04623047	Infection Watch Study	No drug interventions	Not Available	Not Available	completed
NCT02624947	A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization	No drug interventions	prevention	3	completed
NCT01230645	RV568 - Viral Challenge With RSV	No drug interventions	treatment	1	completed
NCT03629145	Music Therapy With Intubated and Sedated Pediatric Patients	No drug interventions	supportive_care	Not Available	completed
NCT04657198	Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study	Respiratory syncytial virus vaccine, adjuvanted	prevention	2	completed
NCT04065698	Pharmacokinetics and Safety of RV521 Formulations	Sisunatovir	other	1	completed
NCT01459198	Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children	No drug interventions	prevention	1	completed
NCT03213405	A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV	BCG vaccine VPM1002	prevention	1	completed
NCT05169905	A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age	Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis pertactin antigen (formaldehyde inactivated) Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Pentetic acid	prevention	3	completed
NCT02864628	RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.	Modified vaccinia ankara	prevention	1	withdrawn
NCT04056611	Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)	Rilematovir	treatment	2	terminated
NCT02654171	Viral Inhibition in Children for Treatment of RSV	No drug interventions	treatment	2	completed
NCT00192478	Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524	Motavizumab	treatment	1 / 2	completed
NCT03959488	A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children	Nirsevimab Palivizumab	prevention	2 / 3	completed
NCT00504907	Safety Study of Oral BTA9881 to Treat RSV Infection	BTA9881	treatment	1	completed
NCT02237209	Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children	No drug interventions	prevention	1	completed
NCT04138056	A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women	Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis pertactin antigen (formaldehyde inactivated) Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	prevention	2	completed
NCT02202356	A Study of ALS-008176 in Infants Hospitalized With RSV	Lumicitabine	treatment	1	completed
NCT02956837	A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women	No drug interventions	prevention	2	completed
NCT03332459	A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection	Lumicitabine	other	2	completed
NCT06344975	A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults	No drug interventions	prevention	1 / 2	not_yet_recruiting
NCT02794870	Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age	No drug interventions	prevention	1	completed
NCT06363370	Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections	No drug interventions	treatment	3	recruiting
NCT04295070	Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers	No drug interventions	prevention	1	completed
NCT03636906	Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV	Clostridium tetani toxoid antigen (formaldehyde inactivated) Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal polysaccharide vaccine group A Meningococcal polysaccharide vaccine group C Meningococcal polysaccharide vaccine group W-135 Meningococcal polysaccharide vaccine group Y Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup b fhbp fusion protein antigen Neisseria meningitidis serogroup b nada protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 14 capsular polysaccharide antigen Streptococcus pneumoniae type 18c capsular polysaccharide antigen Streptococcus pneumoniae type 19f capsular polysaccharide antigen Streptococcus pneumoniae type 23f capsular polysaccharide antigen Streptococcus pneumoniae type 4 capsular polysaccharide antigen Streptococcus pneumoniae type 5 capsular polysaccharide antigen Streptococcus pneumoniae type 6b capsular polysaccharide antigen Streptococcus pneumoniae type 7f capsular polysaccharide antigen Streptococcus pneumoniae type 9v capsular polysaccharide antigen	prevention	1 / 2	completed
NCT06042049	A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab	Nirsevimab	prevention	3	active_not_recruiting
NCT04126213	Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants	No drug interventions	prevention	2	completed
NCT03979313	A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)	Nirsevimab	prevention	3	completed
NCT02753413	Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women	Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis pertactin antigen (formaldehyde inactivated) Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	prevention	2	completed
NCT01302418	Collection and Testing of Respiratory Samples	No drug interventions	Not Available	Not Available	completed
NCT01797419	Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)	Presatovir	treatment	1	withdrawn
NCT05017519	Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT05562817	The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan	No drug interventions	Not Available	Not Available	recruiting
NCT03102034	Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age	No drug interventions	prevention	1	completed
NCT04886596	Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	active_not_recruiting
NCT00232635	A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT	A-60444	treatment	2	completed
NCT00609635	Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly	No drug interventions	Not Available	Not Available	completed
NCT05281263	Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults	No drug interventions	prevention	1	completed
NCT00658086	Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)	Asvasiran	treatment	2	completed
NCT02952339	Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age	No drug interventions	prevention	1	completed
NCT05238025	MVA-BN-RSV Vaccine Trial	Modified vaccinia ankara Tromethamine	prevention	3	completed
NCT02878330	A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.	Nirsevimab	prevention	2	completed
NCT01922648	RSV Observational Study 2	No drug interventions	Not Available	Not Available	completed
NCT02247726	RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.	No drug interventions	prevention	2	completed
NCT00420966	Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy	No drug interventions	Not Available	Not Available	completed
NCT02094365	A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model	Lumicitabine	treatment	2	completed
NCT06102174	A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV	Sisunatovir	other	1	recruiting
NCT05655182	A Study of BLB-201 RSV Vaccine in Infants and Children	No drug interventions	prevention	1 / 2	recruiting
NCT02040831	Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children	No drug interventions	prevention	1	completed
NCT02927873	A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants	No drug interventions	prevention	1 / 2	completed
NCT00031473	Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients	Ribavirin	prevention	3	terminated
NCT03614676	A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance	No drug interventions	screening	Not Available	completed
NCT02673476	A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus	Lumicitabine	treatment	2	completed
NCT06374394	A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	active_not_recruiting
NCT02297594	Safety, Tolerability and PK Study of AK0529 in Healthy Human	No drug interventions	treatment	1	completed
NCT00435994	Assessment of Airway Obstruction in Infants With Lower Respiratory Infections	Ephedrine Epinephrine Guaifenesin	treatment	Not Available	completed
NCT04980391	A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers	No drug interventions	prevention	3	terminated
NCT00384462	Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants	No drug interventions	Not Available	Not Available	completed
NCT02984280	Specific Respiratory Infections as Triggers of Acute Medical Events	No drug interventions	Not Available	Not Available	completed
NCT03227029	Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age	No drug interventions	prevention	1	completed
NCT03757429	Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus	No drug interventions	Not Available	Not Available	completed
NCT06534892	An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	recruiting
NCT05045144	A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.	No drug interventions	prevention	3	completed
NCT05705440	A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control	No drug interventions	other	3	recruiting
NCT04231968	A Study of AK0529 in Chinese Infants Hospitalized With RSV	Ziresovir	treatment	3	completed
NCT02114268	A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults	Nirsevimab	prevention	1	completed
NCT04785612	Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults	No drug interventions	prevention	2	completed
NCT03656510	Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection	Rilematovir	treatment	2	terminated
NCT06551181	A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older	Respiratory syncytial virus vaccine, adjuvanted	prevention	3	recruiting
NCT02890381	Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age	No drug interventions	prevention	1	terminated
NCT06287450	A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults	No drug interventions	prevention	1	not_yet_recruiting
NCT06083623	A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants	No drug interventions	prevention	2 / 3	not_yet_recruiting
NCT03715023	Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients	No drug interventions	treatment	2	terminated
NCT01349543	The Development of a Human Model of Respiratory Syncytial Virus Infection	No drug interventions	basic_science	Not Available	completed
NCT03099291	Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age	No drug interventions	prevention	1	completed
NCT05238974	A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants	Nirsevimab	prevention	3	active_not_recruiting
NCT03422237	Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age	No drug interventions	prevention	1	active_not_recruiting
NCT00001903	Prevention of RSV Infections in Bone Marrow Transplant Recipients	No drug interventions	treatment	4	completed
NCT05687279	Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)	No drug interventions	prevention	1 / 2	active_not_recruiting
NCT04491877	Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers	No drug interventions	prevention	1 / 2	completed
NCT01537198	Surveillance of Synagis in Korean Pediatric Patients	No drug interventions	Not Available	Not Available	completed
NCT06551506	The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products	Nirsevimab Recombinant stabilized RSV A prefusion F antigen Recombinant stabilized RSV B prefusion F antigen	prevention	4	not_yet_recruiting
NCT00593918	Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children	No drug interventions	Not Available	Not Available	completed
NCT06194318	First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults	No drug interventions	prevention	1	recruiting
NCT06251024	Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older	No drug interventions	prevention	2	recruiting
NCT06237296	Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older	No drug interventions	prevention	1	active_not_recruiting
NCT01107535	Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection	Palivizumab	Not Available	Not Available	completed
NCT06079320	A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection	Sisunatovir	treatment	2 / 3	recruiting
NCT01466062	Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions	Palivizumab	prevention	3	completed
NCT01297504	A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America	No drug interventions	Not Available	Not Available	completed
NCT06424795	Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants	No drug interventions	Not Available	Not Available	completed
NCT02135614	Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection	Presatovir	treatment	2	completed
NCT01909843	ALX-0171 Safety Study in Adults With Hyperresponsive Airways	Gontivimab	treatment	1	completed
NCT02016690	Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®	No drug interventions	Not Available	Not Available	completed
NCT02254421	Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract	Presatovir	treatment	2	completed
NCT03473002	A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults	No drug interventions	prevention	1	completed
NCT06546800	SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER	Recombinant stabilized RSV A prefusion F antigen Recombinant stabilized RSV B prefusion F antigen	Not Available	Not Available	not_yet_recruiting
NCT06134648	Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate	No drug interventions	prevention	1 / 2	active_not_recruiting
NCT02309320	A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171	Gontivimab	treatment	1 / 2	completed
NCT06206720	A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV	No drug interventions	treatment	2	recruiting
NCT04767373	Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)	Clesrovimab	prevention	2 / 3	completed
NCT01006629	Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children	Palivizumab	prevention	2 / 3	completed
NCT05987072	A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.	Sisunatovir	other	1	completed